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Abstract
Background: Plasmodium falciparum infections could lead to severe malaria, principally in non-immune individuals
as children and travellers from countries exempted of malaria. Severe malaria is often associated with the
sequestration of P. falciparum-infected erythrocytes in deep micro-vascular beds via interactions between host
endothelial receptors and parasite ligands expressed on the surface of the infected erythrocyte. Although,
serological responses from individuals living in endemic areas against proteins expressed at surface of the infected
erythrocyte have been largely studied, seldom data are available about the specific targets of antibody response
from travellers.
Methods: In order to characterize antigens recognized by traveller sera, a comparison of IgG immune response
against membrane protein extracts from uninfected and P. falciparum-infected red blood cells (iRBC), using
immunoblots, was performed between non exposed individuals (n = 31) and briefly exposed individuals (BEI) (n =
38) to malaria transmission.
Results: Immune profile analysis indicated that eight protein bands from iRBC were significantly detected more
frequently in the BEI group. Some of these antigenic proteins were identified by an original immuno-proteomic
approach.
Conclusion: Collectively, these data may be useful to characterize the singular serological immune response
against a primary malaria infection in individuals briefly exposed to transmission.
Background
The protozoan parasite Plasmodium falciparum is the
causative agent of the most virulent form of human
malaria, affecting about 500 million of persons yearly
and leading to nearly two million deaths, mainly in
Africa [1]. Individuals residing in endemic areas of para-
site transmission acquired gradually a protective immu-
nity to P. falciparum malaria after numerous disease
episodes during childhood. This immunity is not
sterilizing but is protective against clinical disease and
especially severe malaria [2,3]. Children from endemic
areas and travellers from non-endemic countries, con-
sidered as non-immune individuals, are particularly at
risk of dying from severe malaria [4].
Blood stages of P. falciparum are responsible for all
the clinical symptoms of malaria including severe cases
such as severe anaemia or visceral disorders [5]. These
visceral disorders are associated with sequestration of
infected red blood cells (iRBC) [6,7]. This sequestration
phenomenon is due to interactions between endothelial
receptors and parasite proteins expressed at the surface
of iRBC. The abundance and the long time display of
the blood-stage malaria parasites in the human host
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render the proteins from the erythrocytic parasite stages
an important target for the immune system. The
absence of antigen processing in erythrocytes prevents
the iRBC destruction by specific MHC-restricted T-cell
response. Immunity to blood stage malaria parasites is
thus primarily conferred by humoral immune responses
[8]. Additionally, the passive transfer of IgG from highly
exposed individuals (HEI) to non-immune patients
could confer a protective effect to clinical symptoms of
malaria [8-10]. Among proteins supposed to induce a
protective immunity, the surface-expressed P. falci-
parum erythrocyte protein 1 (PfEMP-1) have been lar-
gely studied [11-13]. However, others erythrocytic
parasite stage proteins were reported to elicit an
immune response [14-17]. Collectively, these data sug-
gest that analysis of the serological immune response
from exposed individuals to malaria (briefly or continu-
ously) could be informative for the understanding of the
protective immune response development.
Serological responses from individuals living in hyper-
endemic areas for malaria have been largely studied.
Several blood stage antigens have been characterized,
and some of them are candidates for vaccine trials (for
review [18,19]). Although some studies have assessed
the antibody response to pre-erythrocytic antigens in
travellers [20-22], seldom data are available concerning
the antibody response against blood stage antigens from
non-immune healthy adults briefly exposed to malaria
transmission, such as travellers or individuals living in
area where malaria is under elimination.
The aim of this study was to identify iRBC membrane
antigenic protein repertoire recognized specifically by
briefly exposed individuals (BEI). An immunoblot
approach allowed us to define a singular BEI IgG
response against membrane protein extract from iRBC
compared to non-exposed individuals (NEI). This speci-
fic serological immune response could be useful to esti-
mate individual exposure to malaria transmission, and
to understand the first stages of the immune responses
to primary malaria infection.
Methods
Population studied
Five French soldier companies (n = 751, mean age ± SD:
25.3 ± 4.8 years), who travelled during a five-month per-
iod in tropical Africa (Gabon or Ivory Coast, from 2002
to 2007), were included in this study. Individuals used
mandatory anti-malaria prophylaxis including anti-vec-
torial equipment, such as permethrin-impregnated bed
nets, repellents and long-sleeve battle dress at night and
chemoprophylaxis (100 mg of doxycycline per day).
Blood samples were collected one week after the return
to France and sera were stored at -80°C. Sera from indi-
viduals living in France (n = 31, mean age ± SD: 31.2 ±
6.5 years, Caucasians), who have never been exposed to
malaria vectors and parasite were used as negative con-
trols. Sera from highly exposed individuals (HEI) to
malaria from Congo (n = 9), gratefully provided by Pr.
Hovette (Centre médical de secours Total, Pointe Noire,
Republic of the Congo) and from Senegal (n = 5), were
used as positive controls. All participants gave their
written informed consent to take part in the study and
Marseille-2 University ethical committee has approved
the protocol (Ethics Statement).
Parasite culture
The RP8 P. falciparum cytoadherent strain was selected
from the Palo Alto (FUP)1 strain by panning on Human
Umbilical Vein Endothelial Cells (HUVEC, ATCC num-
ber: PCS-100-010), as described by Fried and Duffy [23].
This cell line express CD36 and ICAM-1 which are well
known host receptors involved in cytoadherence of
iRBC. Parasites were maintained in continuous culture
in candle jar as previously described [24,25]. Briefly,
parasites were cultured at 5% haematocrit of type O+
human RBC suspended in RPMI 1640 (Invitrogen, Pais-
ley, UK) supplemented with 25 mM HEPES (Invitrogen),
6 mM D-glucose (Sigma-Aldrich, St Louis, USA), 23
mM NaHCO3 (Invitrogen), 32 μg/ml neomycine (Sigma-
Aldrich), 0.2 mM L-glutamine (Invitrogen), 0.25 μg/ml
orotic acid (Sigma-Aldrich), 0.5 μg/ml hypoxanthine
(Sigma-Aldrich) and 10% of heat-inactivated type O+
human serum, at 37°C in a gas mixture of 3% CO2, 17%
O2. Parasitaemia and erythrocytic cycle stages propor-
tion were monitored daily microscopically by examina-
tion of blood smear stained with Giemsa-stained (RAL®
555, France).
Liquid indirect immunofluorescence assay (L-IFA)
RBC and iRBC from in vitro cultures with about 10%
parasitaemia were used to perform L-IFA as previously
described [26,27]. Briefly, 50 μl of cell suspension were
washed two times in RPMI 1640 at room temperature
and incubated in DAPI (40 μg/ml) (Invitrogen, USA) for
30 min at 37°C. After 3 washing in PBS (Invitrogen),
immuno-staining was started by incubating cells with 50
μl of diluted sera for 30 min on ice. Each sera was indi-
vidually analysed using dilutions of 1:40, 1:80, 1:160,
1:320, 1:640 and 1:1,280 in PBS pH 7.4. Positive and
negative control sera were used at 1:40 dilution. After
two washes with RPMI 1640, alexa-fluor 488 goat anti-
human immunoglobulin G (H+L) (Molecular Probes,
USA) was added to the cell suspension and incubated
for 30 min on ice. A droplet of cell suspension was laid
on a microscopy slide, and antibody binding and DNA
staining were assessed by fluorescence microscopy on a
Nikon eclipse E800 fluorescence microscope (100 ×
magnification). Sample titres were determined by the
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maximum dilution where the fluorescence could be
detected.
Sample preparation
Plasmodium falciparum adherent mature stages (tropho-
zoite and schizonte stages) were enriched by Plasmion
flotation (Fresenius France Pharma, Louvier, France) as
described elsewhere [25,28]. Infected erythrocytes were
washed two times in PBS medium and lysed in cold
hypotonic medium (H2O-saponin 0.1%, Sigma) for
2 min. Free parasites were discarded by centrifugation
(9 300 × g for 4 min). Erythrocyte membranes were
recovered from the supernatant, and this cell fraction
was submitted to repeat steps of ultra centrifugations
(100 000 × g for 1 h at 4°C) followed by washing until
iRBC ghost were colourless, and stored at -80°C. The
same protocol was used to collect membrane proteins
from uninfected erythrocytes. Membrane protein extracts
were then suspended in 4% (w/v) CHAPS (Sigma). Mem-
brane aggregates were then disrupted by ultrasonication
(Vibracell 72412, Bioblock Scientific, Illkirch, France) for
5 min on ice at maximum amplitude and precipitated in
100% acetone (Sigma) to discard lipids. Protein concen-
tration was estimated using Lowry-based DC assay
(Biorad, Hercules, CA, USA) according to the manufac-
turer’s instruction. Membrane protein extracts were sus-
pended in a buffer containing 8 M urea (Sigma), 2 M
thiourea (Sigma), 4% (w/v) CHAPS (Sigma) and 30 mM
Tris (Sigma), adjusted to pH 8.5 in order to obtain a pro-
tein concentration adjusted to 2.5 μg/μL.
Immunoblots and analysis procedures
The RBC and iRBC membrane samples were reduced in
a Tris buffer containing dithiothreitol (1% w/v, Sigma),
and 15 μg of each sample were loaded per well onto a
10% polyacrylamide gel before to be separated by SDS-
PAGE in a Mini PROTEAN II (BioRad, Hercules, CA,
USA). After SDS-PAGE, gels were transferred onto a
nitrocellulose membrane (0.45-μm, GE Healthcare) by
semidry blotting [29]. Each membrane was cut into 18-
22 strips (3-4 mm wide), before incubation with a
saturation buffer (5% non-fat dried milk in PBS contain-
ing tween-20 (0.1% v/v, Sigma)). Immunoblots were car-
ried out with human sera, which were diluted at 1/100
in saturation buffer. After overnight incubation, blots
were incubated with mouse anti-human Fcg/IgG horse
radish peroxidase (HRP) conjugated antibody (1/5 000,
Beckman Coulter, San Jose, CA, USA), and revealed
using an ECL Plus western blotting (WB) detection sys-
tem (GE Healthcare). Densitometric analysis of autora-
diographs was performed using Diversity database™2.2
software (Biorad) to align and compare the IgG immune
patterns. Two sera, one from a NEI and another one
from a HEI which were used as controls, were tested on
each blot in order to assess the quality of each immuno-
blot and to improve the accuracy of the alignment of
antibody reactivities intra- and inter-gels [30,31]. Mole-
cular weights were estimated by comparison with stan-
dard molecular weight (Biorad).
CyDye labelling
Membrane proteins from iRBC were minimally labelled
with CyDye according to the manufacturer’s recom-
mended protocols (GE Healthcare). Briefly, membrane
protein extracts (50 μg) were labelled with 400 pmol of
Cy5, freshly dissolved in anhydrous dimethyl formamide
(Sigma), and incubated on ice for 30 min in the dark.
The reaction was quenched with 1 μL of free lysine (10
nM, Sigma) by incubation 10 min on ice. An equal
volume of 2× sample buffer (8 M urea, 2 M thiourea,
4% (w/v) CHAPS, 10 mM DTT, 1% (v/v) IPG Buffer 3-
10 (GE Healthcare) was added to the Cy5 labelled sam-
ple before submission to two-dimensional electrophor-
esis (2-DE).
Two-dimensional electrophoresis (2-DE)
Reagents that were not purchased from GE Healthcare,
are indicated. Destreak buffer containing 1% (v/v) IPG
buffer 3-10 was used for IPG strips (18-cm) overnight
rehydratation. The samples were laid at the acidic end
of the IPG strip using a cup-loading technique. IEF was
carried out on an Ettan IPGphor II electrophoresis unit
at 20°C, for a total of 45 kVh. Prior to separation in the
second dimension, IPG strips were reduced and alky-
lated in a equilibration buffer containing 50 mM Tris-
HCl, pH 8.6 buffer, 6 M urea, 2% SDS and 30% glycerol
supplemented with 1% (w/v) DTT or 2.5% (w/v) iodoa-
cetamide instead of DTT for 10 min. IPG strips were
then placed on the top of 10% uniform polyacrylamide
gels. Strips were overlaid with 0.5% agarose in 1× run-
ning buffer containing bromophenol blue and the pro-
teins were further separated by SDS-PAGE (15 W per
gel) at 20°C, in Ettan DALT Six electrophoresis system.
Two-dimensional gels were either stained with Imper-
ial™Protein Stain (Thermo Scientific, Rockford, IL, USA)
or transferred onto nitrocellulose membranes and incu-
bated with human sera as described above (see Materials
and Methods section: immunoblots and analysis proce-
dures). For nitrocellulose membranes with Cy5-labelled
proteins, antibody response was revealed using goat-
anti-human IgG FITC-conjugate (diluted at 1:2000)
(Invitrogen). Immunoblots were directly digitalized
using a Typhoon™Trio Image scanner. Images were ana-
lysed with Decyder v6.5 software, allowing an accurate
spot matching between 2-D protein patterns and 2-D
antigenic patterns from gels and immunoblots respec-
tively. Matched spots were selected for excision and
further identification by mass spectrometry (MS).
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Spots excision and in-gel digestion
Based on Decyder analysis, spots of interest were
excized using Shimadzu Biotech Xcise System (Champs
sur Marne, France). Protein spots were digested over-
night at 37°C with sequencing-grade trypsin (12.5 μg/
mL; Promega Madison, WI, USA) in 50 mM NH4HCO3
(Sigma). The resulting peptides were extracted with 25
mM NH4HCO3 for 15 min, dehydrated with acetonitrile
(ACN) (Sigma), incubated with 5% acid formic (Sigma)
for 15 min under agitation, then dehydrated with ACN,
and finally completely dried using a SpeedVac. Samples
were then stored at -20°C before analysis by mass spec-
trometry (MS).
Mass spectrometry analysis
The samples were analysed on a LCQ DecaXPplus (Ther-
moFinnigan, San Jose, CA) ion trap. Nano-liquid separa-
tion of peptides was carried out using an Ettan MDLC
chromatographic system (GE Healthcare) in high
throughput configuration. Ten microliters of the digest
were first trapped on a zorbax 300SB-C18 5 × 0.3 mm
column and eluted at a flow rate of approximately 200
nL/min on a zorbax 300SB-C18, 3.5 μm, 150 × 0.075 mm
by a linear gradient of eluant B (0.1% Formic acid, 84%
ACN) in eluant A (1% Formic acid). Chromatographic
system was piloted by Unicorn 5.01 software (GE Health-
care). MS measurements were performed using a
LCQTM Deca XP Plus ion trap mass spectrometer
(ThermoFinnigan) equipped with a LCQTM nanospray
ionization source. A spray voltage of 1.8 kV was applied
to the liquid junction via an in-union high voltage con-
tact coupled to a silicaTip emitter (New Objective).
Operation of the mass spectrometer was fully automated
during the entire procedure using Excalibur 1.3 data sys-
tem (ThermoFinnigan). Continuous cycles of one full
scan (m/z 500 to 1700) followed by three data-dependent
MS/MS measurements at 35% normalized collision
energy were performed. MS/MS measurements were
allowed for the three most intense precursor ions with a
maximum rejection time limit of 1 min. All MS/MS spec-
tra were sequence database searched using Mascot Dae-
mon v2.2.2 software (Matrix Science, London, UK).
MS data analysis
The data were searched using Mascot software, against
Homo sapiens and P. falciparum National Center for
Biotechnology Information non-redundant (NCBInr,
NIH, Bethesda, MD) protein database (June 10th, 2009).
Search parameters are set in order to allowed for one
missed tryptic cleavage site, the carbamidomethylation
of cysteine, and the possible oxidation of methionine;
precursor and product ion mass error tolerance was
<0.2 Da. All identified proteins have a Mascot score
greater than 41 (Mixed: H. sapiens + P. falciparum,
237,583 sequences), corresponding to a statistically sig-
nificant (p < 0.05) confident identification. Moreover,
among the positive matches, only protein identifications
based on at least two different non-overlapping peptide
sequences with a mass tolerance <0.05 Da were
accepted. For single peptide-based identification, in
addition to Mascot score significance, were considered
only peptide sequence with at least six consecutive
amino acids detected on MS spectra (Additional file 1).
These validation criteria were added in order to limit
the number of false positive matches without missing
real proteins of interest.
Statistical analysis
For IgG antibody patterns analysis, the data were
expressed in binary mode (0, absence of antigenic band;
1, presence of an antigenic band). The Mann-Whitney
and the Fisher exact test were used as appropriate. All
statistical analyses were done with the SPSS 12.0
software.
Results
BEI sera selection according to their IgG reactivity against
iRBC surface proteins
IgG antibody reactivity from 751 BEI sera sampled after
a five months journey in endemic area was assessed by
liquid-indirect immunofluoresence assay (L-IFA). Con-
sidering reactions with titres over 1:80 as positive, 38
BEI sera (5.0%) shown an IgG reactivity directed against
the surface of iRBC (Figure 1). Among the 38 selected
BEI, 37 were males with a mean age ± SD of 25 ± 3.5
years. Eight BEI had a P. falciparum clinical episode
during the journey. These positive BEI sera were
selected for 1 D immunoblotting analysis. Sera from
individuals never exposed to malaria (NEI, n = 31) were
also tested by L-IFA, and none of them presented IgG
reactivity against iRBC at 1:40 dilution (Figure 1). Sera
from highly exposed individuals (HEI, n = 14) presented
a high IgG reactivity against the surface of iRBC until
dilution to 1:320.
Comparative IgG responses against RBC and iRBC
membrane protein extracts between NEI, BEI and HEI
The IgG antibody response of selected sera from NEI (n
= 31), BEI (n = 38) and HEI (n = 14), was tested succes-
sively against RBC and iRBC membrane protein extracts
using immunoblots (Figure 2A &2B). The densitometric
analysis of the different patterns of proteins recognized
by IgG obtained with regard to the molecular mass,
were performed for quantitative comparisons. Against
RBC membrane protein extracts, 3.4 ± 2.6 (means ±
SD), 3.5 ± 2.1 and 4.9 ± 1.5 antigenic bands were
detected per strip for NEI, BEI and HEI sera, respec-
tively (Figure 2C). The number of antigenic bands
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recognized by each sera group, against RBC membrane
protein extracts, was low and no significant difference
was observed between these groups (Mann-Whitney
test, p > 0.05). Against iRBC membrane protein extracts,
3.4 ± 2.0 (means ± SD), 8.1 ± 4.4, 19.9 ± 4.0 antigenic
bands were detected per strip for NEI, BEI and HEI
sera, respectively (Figure 2C). In this case, the number
of antigenic bands recognized by BEI and HEI groups
were significantly more important compared to NEI
group (Mann-Whitney test, p = 1.6 × 10-7 and p = 4.5 ×
10-7 respectively). Moreover, the number of antigenic
bands detected between RBC and iRBC membrane pro-
tein extracts is significantly increased for BEI (Mann-
Whitney test, p = 8.2 × 10-8) and HEI (Mann-Whitney
test, p = 4.9 × 10-8). For NEI group, between RBC and
iRBC membrane protein extracts, the number of anti-
genic bands detected was not significantly changed
(Mann-Whitney test, p > 0.05). Collectively, these results
suggest that individuals exposed to P. falciparum para-
sites (BEI and HEI) present an IgG immune response
specifically directed against iRBC membrane protein
extracts. It is interesting to note that no antigenic bands
could be detected above 200 kDa.
Determination of antigenic bands recognized by BEI sera
In order to define band identity of antigens recognized
by BEI, a qualitative analysis of the IgG immune
response was performed between NEI and BEI groups.
A mapping and alignment of the IgG patterns allowed
us to detect a total of 23 and 36 distinct antigenic bands
against RBC and iRBC membrane protein extracts,
respectively. Against RBC membrane protein extracts,
no antigenic band was significantly detected more fre-
quently in one group than to the other one (Fisher
exact test, p > 0.05). Conversely, against iRBC mem-
brane protein extracts, eight antigenic bands were signif-
icantly detected more frequently in BEI group compared
to NEI group (Fisher exact test, p < 0.05; Figure 2D).
Each of these antigenic bands was detected by at least
20% of BEI (Figure 2D). Additionally, each BEI sera
recognized at least two of the eight selected antigenic
bands. The molecular weights of these antigenic bands
ranged from 18 kDa to 130 kDa, and a schematic repre-
sentation of these antigenic bands was depicted on an
immunoreactivity diagram (Figure 2E). Among the BEI
group, five sera were selected with regard to their IgG
response on 1-D immunoblots for subsequent antigens
identification. Each selected BEI sera recognized at least
three of the eight discriminatory antigenic bands and
the pool covered the whole spectrum of these antigenic
bands against iRBC membrane protein extracts. The
pool was composed of these five selected BEI sera.
Characterization of iRBC membrane antigens recognized
by BEI
To further characterize these discriminatory antigens, a
2-D immunoproteomic approach was adopted. A major
difficulty of this approach is to perform a perfect match
between antigenic spots detected on 2-D immunoblot
and their counterparts on the preparative gel, on which
matched spots will be excized and further analysed by
mass spectrometry (MS). As the results of these protein
Figure 1 Evaluation of human serological response against RBC infected by RP8 P. falciparum strain by liquid indirect
immunofluorescence assay (L-IFA). Representative IgG response against iRBC from a non-exposed individual (NEI, upper row) and a briefly
exposed individual (BEI, lower row) to malaria, are shown. Specific antibody response to surface proteins from live iRBC was revealed with alexa
488 goat anti-human IgG antibodies (green). P. falciparum DNA was stained with DAPI (blue), and merged images with bright field (BF) are
shown (Magnification × 100).
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identifications are the starting point of further studies, it
is necessary to limit miss matching. Thus, 2-D immuno-
blot using a fluorescence-based method allows to
increase considerably the confidence in spot matching
between preparative gel and immunoblots (Figure 3).
The pool of BEI sera allowed to detect 42 antigenic
spots onto the 2 D immunoblot (Figure 4). To facilitate
the alignment of the antigenic bands with the corre-
sponding spots between 1 D and 2 D immunoblot, iRBC
membrane protein extracts were loaded onto 2 D gel
beside the IPG strip, prior electrophoresis, as described
previously [30]. For seven out of eight antigenic bands
selected by 1 D analysis, their corresponding spots were
detected onto 2 D immunoblot (Figure 4). No antigenic
spot corresponding to the molecular weight (MW) of
band “V” was detected onto 2 D immunoblot. This
could be attributable to the extremes pI or low solubility
of this antigenic protein in the buffer for 2DE.
As some bands split into several protein species, 30
spots were assigned to the seven antigenic bands (Figure
4, Additional file 2). A typical example is presented by
the antigenic band number “I” which can be resolved
into nine different spots on the 2-D immunoblot. The
42 antigenic spots detected onto the immunoblot, were
excized and submitted to MS for identification (Figure
4). The resulting fragment ion spectra were searched
against H. sapiens and P. falciparum-protein databases
(NCBInr). Nineteen protein spots (45%) were success-
fully identified and correspond to 13 distinct proteins
according to their NCBI accession number (Additional
Figure 2 Analysis of immune response against iRBC membrane protein extracts using sera from non-exposed individuals (NEI), briefly
exposed individuals (BEI) or highly exposed individuals (HEI) to malaria. IgG immune profiles from 4 NEI, 6 BEI and 2 HEI revealed by
immunoblotting against erythrocyte membrane protein extracts from RBC (A), or iRBC (B) are presented. Two human sera, “Ctrl NEI (-)” and “Ctrl
HEI (+)”, loaded on each blot, were used as controls for antibody revelation and migration quality. MW: molecular weight, kDa: kiloDalton. (C)
Comparative analysis of the antigenic bands number recognized by sera from NEI, BEI and HEI against RBC and iRBC membrane protein extracts.
For this quantitative analysis, significant differences are indicated for each group tested between the two membrane protein extracts (p < 0.05,
Mann-Whitney test). The line within the box represents the mean number of antigenic bands recognized by each sera group. The boundaries of
the box indicate the 25th and 75th percentiles. Whiskers above and below the box indicate the maximum and minimum values. (D) Frequency
of iRBC membrane antigenic protein bands detected by NEI and BEI. Analysis of IgG profiles using diversity database software (Biorad) allowed
us to exhibit 8 antigenic bands from iRBC membrane protein extracts statistically significant (Fisher exact test, *p < 0.05; **p < 0.01, ***p < 0.001)
between NEI and BEI groups. Only protein bands significantly different between NEI and BEI and detected by at least 20 percent of the
individuals from a group were indicated. (E) These antigenic bands are indicated on a diagram using Roman numeral numbers, and their
corresponding molecular weights are indicated in brackets.
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file 2). Among them, four were identified as P. falci-
parum proteins and nine as H. sapiens proteins. Selected
bands “I”, “II” and “VII” were identified as H. sapiens
antigens and selected bands “III”, “IV” and “VI” as P. fal-
ciparum antigens. However, MS did not identify protein
spots corresponding to the selected band “VIII”, despite
their apparent high abundances. This could be attributa-
ble to the low MW of these spots giving spectra with
low complexity. Thus, spots corresponding to six out of
eight antigenic protein bands were identified.
Discussion
A recent study performed in the laboratory shown that
35% of soldiers who travelled for a few month period in
tropical Africa, presented a serological response against
pre-erythrocytic antigens. Among them, only 2% had
experienced a clinical malaria attack [22]. Others have
reported that travellers from malaria-free countries can
develop antibody response against pre-erythrocytic
[20,21] and blood stages [32]P. falciparum antigens
without progressing to a symptomatic illness. Thus, the
characterization of erythrocytic stage antigens specifi-
cally detected by healthy adults shortly exposed to
malaria and under chemoprophylaxis could be informa-
tive to estimate individual exposure to malaria transmis-
sion, and to clarify the mechanisms involved in the
development of immune responses after malaria infec-
tion. In this aim, a comparison and an analysis of
Figure 3 Schematic representation of experimental workflow for an accurate identification of antigenic protein using 2-D immunoblot
with a fluorescence-based method. The different steps are numbered from #1 to #6. Briefly, iRBC membrane protein extracts were pre-labelled
with Cy5 cyanine (#1), separated by 2-D electrophoresis (#2), electroblotted onto membranes, probed with the pool from 5 selected BEI sera and
incubated with a goat-anti-human IgG FITC-conjugate (#3). Following blot digitalization at Cy5 and FITC wavelengths (#4), two images
corresponding respectively to the antigenic protein pattern and the total protein expression profile were obtained. The superimposition of these
two images (#5) allowed us to excize accurately spots of interest on preparative gel run in parallel (#3’), before to submit them to mass
spectrometry (MS) for identification (#6). Protein expression profile was used as “internal standard” to perform a perfect match between the blot
and the preparative gel.
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serological responses between NEI, BEI and HEI against
membrane protein extracts from uninfected and P. falci-
parum infected RBC were performed. Although the use
of a prophylactic treatment limiting the abundance of
the blood malaria parasite could affect the antibody
response development, it was observed that 5% of sol-
diers shown an IgG reactivity directed against the sur-
face of iRBC. Among them, only a minor part (21%)
presented a history of clinical malaria. Thus, although
exposure to malaria transmission was brief and probably
low because of the use of chemoprophylaxis and anti-
vector devices, some BEI could develop an antibody
response against blood stage antigens without history of
clinical malaria attacks.
Analysis of IgG immune response indicated an asso-
ciation between the exposition level and the number of
bands revealed by 1-D immunoblotting against iRBC
membrane protein extracts. A thorough qualitative ana-
lysis of the immune profiles shown that eight protein
bands from iRBC membrane protein extracts were sig-
nificantly more frequently recognized by BEI sera than
NEI sera. To identify unambiguously these antigenic
bands, an original 2-D immunoproteomic approach
using a fluorescence-based method was performed.
Almeras et al previously demonstrated that it was possi-
ble to align, with a good confidence, antigenic bands
detected by 1 D immunoblot with the corresponding
spots onto 2 D immunoblot [30]. Here, this study
shown that a perfect match is now conceivable between
antigenic spots from the blot and their corresponding
spots from the preparative gel, as recently described by
Donoghue et al [33]. This method allowed us to identify
13 protein spots corresponding to six out of the eight
antigenic bands.
Surprisingly, spots corresponding to bands “I”, “II” and
“VII” were identified as H. sapiens proteins. Auto-anti-
bodies (aabs) against RBC membrane proteins have been
already described in malaria patient’s sera [34,35]. Little
is known about the mechanisms that underlie the aabs
production during parasite infection. Aabs production
could arise from cross reactivity between host and para-
site antigens. This molecular mimicry phenomenon
could reduce the tolerance to self antigens and develop
an auto-immunity during parasite infection [36]. How-
ever, here, all discriminatory antigenic proteins were
exclusively recognized on iRBC membrane protein
extracts (Additional file 3). The aabs emergence against
host proteins on iRBC membrane protein extracts could
be attributed to others phenomenon such as protein
post-translational modifications. Effectively, it was
demonstrated that protein phosphorylations of host and
parasite occur during P. falciparum infections [37,38].
Moreover, ankyrin (gi|178646; band “I”), which was
identified as a host discriminatory antigenic protein, was
reported to be targeted by falcipain-2, a P. falciparum
protease [39]. This protein cleavage could produce neo-
antigens which are then recognized only in infected con-
ditions. Nevertheless, aabs directed against these struc-
tural membrane proteins were also observed in other
Plasmodium species infections [35] and could occur in
Figure 4 Determination of protein spots detected by BEI sera on iRBC membrane protein extracts by 2-D immunoblotting. A 2-D
immunoblot using a fluorescence-based method was performed to detect precisely and accurately antigenic protein spots. (A) Protein profile of
iRBC membrane protein extracts pre-labelled with Cy5 and separated by 2-D electrophoresis. (B) Protein profile of the same protein sample used
in “A” after Cy5 labelling, separation by 2-D electrophoresis and electroblotting onto nitrocellulose membrane. (C) Immunoblot pattern of a pool
of 5 selected BEI sera revealed with a goat-anti-human IgG FITC-conjugate against iRBC membrane protein extracts. (D) Merged images of the
electrobloted protein profile (e.i., “B”) and the immunoblot pattern (e.i., “C”). Antigenic spots detected onto immunoblot (e.i., “C”) are ringed and
reported onto electrobloted protein profile (e.i., “B”) and merged images (e.i., “D”). Antigenic spots which were excized for mass spectrometry
(MS) analysis are marked with red or green circles onto gel image and those which were identified are indicated by Arabic numbers (e.i., “A”).
Selected antigenic bands are indicated by Roman numbers and positioned according to their MW. Antigenic spots corresponding to selected
antigenic bands are indicated by red circles, the others antigenic spots are assigned by green circles (A). A resume of the correspondence
between Roman and Arabic numbers is indicated in additional file 2. MW: molecular weight, kDa: kiloDalton.
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other diseases involving RBC abnormalities like thalas-
saemia or autoimmune haemolitic anaemia [40,41].
Despite a significant recognition of these host proteins
by BEI sera, these discriminatory proteins did not seem
to be relevant markers of malaria exposure. Another
explanation of the identification host proteins could be
attributed to that the spotted area could contain a mix-
ture of both parasitic and human proteins, and the
amount of parasite proteins is under-represented com-
pared to human proteins, and so parasitic antigenic pro-
teins may be missed by MS.
Four P. falciparum proteins (exported protein 2 (Exp-
2) PF14_0678, band “VI"; early transcribed membrane
protein (Etramp5) PFE1590w, band “VI"; Heat shock 70
kDa protein (Pf-Hsp70-1) PF08_0054, band “III"; elonga-
tion factor 1a (EF1 a) PF13_0304, band “IV”) corre-
sponding to three discriminatory antigenic bands were
also identified. Exp-2 and Etramp5 which are iRBC
membrane associated proteins, have been described to
participate to protein transport between parasite and
iRBC [42-44]. An immune response against these pro-
teins was previously observed using sera of travellers
and individuals from endemic areas [17,44]. The absence
of signal detection by sera from never-exposed indivi-
duals suggests that Etramp5 could be an interesting
marker of P. falciparum exposure.
The Pf-Hsp70 was detected at several parasite stages
into the human host, in sporozoites [45], in liver stage
[46,47], in all parasite blood stages [48,49] or in associa-
tion with the iRBC plasma membrane [42], and is also
possibly present on the merozoite surface [50]. Here, a
specific antibody response against Pf-Hsp70 was
revealed by BEI sera. This protein has been described as
a major target in the acquisition of immunity in natu-
rally infected humans living in areas of endemic malaria
[17,49,51]. Moreover, Pf-Hsp70 is able to elicit protec-
tion of Saimiri sciureus monkey against the asexual
blood stage of P. falciparum [52]. Collectively, these
data suggest that Pf-Hsp70 seems to be an immunodo-
minant antigens following parasite infection, and could
be considered as a biomarker of malaria exposure.
The EF1 a is an abundant protein constituting 1-2%
of the total protein in eukaryotic cells [53], and is an
essential component of the translational machinery. This
protein is involved in other processes as protein degra-
dation, signal transduction and in the regulation of
cytoskeletal rearrangements [54,55]. EF1 a protein was
unambiguously recognized by BEI sera reflecting an
exposition to the immune system. It is the first time
that EF1 a protein was described as antigenic in indivi-
duals exposed to malaria.
The present study failed to identify several well
described P. falciparum antigenic proteins from the
iBRCs plasma membrane. The major part of these P.
falciparum antigens are large hydrophobic proteins
(> 150 kDa) which are generally under represented and
can be difficultly detected on 2-D electrophoresis [56],
such as PfEMP1 [57], Pf332 [58,59], the cytoadherence
linked asexual protein 9 (Clag 9) [60,61] or the erythro-
cyte-binding antigen 175 (EBA-175) [62]. Furthermore,
it was reported that serological immune responses
against several P. falciparum antigens is conformation
dependent [63,64]. Thus, the reducing and denaturing
conditions used for the immunoblot analysis in the pre-
sent study, did not allow to take into consideration con-
formational epitopes. Conversely, antibody reactivities
against linear epitopes derived from PfEMP1 or other P.
falciparum proteins have been already observed under
reducing conditions [65,66]. The non-detection of these
large proteins on 1-D and 2-D immunoblotting could be
then attributed to incomplete protein transfer onto
nitrocellulose membrane as previously described [67].
The use of only one parasite strain with limiting variant
antigen repertoire, for BEI sera selection, could also
induce a bias for identifying more antigenic membrane
parasite proteins. Moreover, Fried et al. reported that
continuous in vitro culture of laboratory isolates could
conduct to the loss or truncation of some parasite pro-
teins [68], which could participate to this underestima-
tion of antigenic parasite protein detection. Additionally,
a lot of known antigens from the asexual blood stage are
proteins from the merozoite surface (eg. MSP1, MSP2 or
RESA) [69]. In the sample condition preparations used
here, iRBC membrane extracts were exempted of mero-
zoites. Moreover, although some merozoite proteins are
described to associate to the iRBC membrane during
merozoite invasion (eg RSP2) [70,71], these proteins are
largely under-representated on the iRBC membrane frac-
tion. Other iRBC membrane proteins such as RIFIN (30-
45 kDa) [72] and STEVOR (30-40 kDa) [73], were
reported to be antigenic in individuals which have experi-
enced several malaria infections [74,75]. A short exposure
to malaria might not be sufficient to induce an antibody
response against these proteins in BEI. However, comple-
mentary methods, such as the screening of P. falciparum
expression library with BEI sera, could be envisaged for
the characterization of others antigenic parasite proteins,
as described previously [76].
The detection of a specific immune response against
iRBC membrane extract could be unexpected using sera
from individuals which have a mandatory chemoprophy-
laxis during their journey. Doxycycline was reported to
be partially efficient on liver stages of P. falciparum
parasites [77], and to alter asexual parasite blood stage
at the end of the second erythrocytic cycle [78,79].
Thus, a possible discontinuity in chemotherapy obser-
vance would have increased the risk to develop a speci-
fic IgG response against blood stage antigens.
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Conclusion
This study provides evidence that some BEI could
develop a singular antibody response against blood stage
antigens after a short exposure to malaria in endemic
area. An original immunoproteomic approach allowed
the identification of some discriminatory antigenic
bands, which corresponded to P. falciparum and H.
sapiens proteins. These antigens may represent promis-
ing erythrocytic biomarkers to estimate individual expo-
sure to malaria transmission, and might help to
understand the first stages of the immune responses to
primary malaria infection. These antigens could be also
useful in the analysis of the host-parasite relationships
among travellers, or individuals living in areas where
malaria is under elimination.
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Additional material
Additional file 1: Single-Peptide-Based Protein Identifications. Single
peptide-based identifications of the “proteasome subunit HsN3,
gi565651” including the spot number, the monoisotopic mass of neutral
peptide, the peptide sequence, the ion score, the expect value and the
Mascot score are indicated in the table. The observed masses as well as
fragment assignments are graphically presented at the bottom.
Additional file 2: Antigenic iRBC membrane proteins detected by
BEI sera. The proteins were identified by LCQ DecaXPplus mass
spectrometer. Band and spot numbers corresponds to numbers indicated
in Figure 2 and Figure 4, respectively. The identities of protein spots,
their NCBI accession numbers, the theoretical and observed MW values,
the pI values, as well as the corresponding percentage sequence
coverage, the number of peptide sequences, and the Mascot score are
listed for MS/MS analysis (Protein scores greater than 41 were considered
as significant (p < 0.05)). *As a single-peptide was used for this protein
identification, the corresponding MS/MS spectrum was included in the
additional file 1.
Additional file 3: Specific antigenic protein profiles recognized by
pooled sera from briefly exposed individuals (BEI). Two-dimensional
immunoblots were performed as described previously [31]. Briefly, RBC or
iRBC membrane protein extracts were resolved by IEF on pH range 3-10
linear IPG strips (7 cm, GE Healthcare). Before SDS-PAGE (10%), 10 μg of
samples were loaded at the left side of the IPG strip, and gels were
electrobloted onto nitrocellulose membrane (GE Healthcare). Five sera
from each group (BEI, non-exposed individuals (NEI) and highly exposed
individuals (HEI)) were selected according to their representative immune
profile on 1 D immunoblot, and were pooled. Each pooled sera were
probed onto 2 D immunoblot, and antigenic protein spots were
revealed using ECL kit on autoradiography X-ray film (GE Healthcare).
Representative 1 D (#) and 2 D antigenic profiles obtained with BEI (A
and B), NEI (C), and HEI (D) pooled sera against RBC (A) or iRBC (B, C and
D) membrane protein extracts are illustrated. Black circles correspond to
antigenic protein spots detected on 2 D immunoblots. Antigenic spots
detected by BEI and NEI or BEI and HEI pooled sera on iRBC membrane
protein extracts are encircled in dashed line (C and D). Roman numbers
correspond to antigenic bands indicated in Figure 2 and additional file 2.
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